Clinical Trials Logo

Clinical Trial Summary

Focal segmental glomerulosclerosis (FSGS) is a condition that harms the kidney "filters" that remove waste from the blood. Proteins are supposed to stay in the blood. Damaged "filters" let protein get into the kidney. FSGS is a serious condition that can lead to kidney failure. The only treatment for kidney failure is dialysis or kidney transplant. Proteinuria means too much protein came through the kidneys into the urine. If the doctor cannot figure out what is causing the problem, it is primary (idiopathic) FSGS. This kind of FSGS is very hard to treat. This study will test Acthar in patients with this condition who have not responded to other treatments. It primarily investigates how well the therapy is tolerated by the patients and how well they respond to this treatment.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms

  • Glomerulosclerosis, Focal Segmental
  • Idiopathic Focal Segmental Glomerulosclerosis
  • Proteinuria

NCT number NCT02633046
Study type Interventional
Source Mallinckrodt
Contact
Status Completed
Phase Phase 4
Start date October 10, 2016
Completion date August 27, 2020